The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
|Articles|July 25, 2012
Healthcare Law now Cheaper, Won't Cover as Many People
Advertisement
President Barack Obama’s health care law just got cheaper — to the tune of $84 billion over 11 years, according to the Congressional Budget Office.
That's because the Supreme Court’s June ruling on the law allowed states to opt out of a costly Medicaid expansion, and in a new report released Tuesday, CBO anticipates that some of them will do just that. As a result, about 3 million more people will remain uninsured, Capitol Hill’s official bean counters said.
Read the full story:
Source: Politico
Advertisement
Related to this article
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
FDA Approves First Symptomatic Dermographism Treatment
4
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
5